These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 30176173

  • 21. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
    Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, Melton LJ, Kumar S, Greipp PR, Clark RJ, Rajkumar SV.
    Leukemia; 2008 Oct; 22(10):1933-7. PubMed ID: 18596742
    [Abstract] [Full Text] [Related]

  • 22. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Ščudla V, Petrová P, Pika T, Lochman P, Minařík J, Bačovský J, Srovnalík K.
    Cas Lek Cesk; 2015 Oct; 154(4):181-8. PubMed ID: 26357861
    [Abstract] [Full Text] [Related]

  • 23. The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function.
    Dimopoulos MA, Kastritis E, Michalis E, Tsatalas C, Michael M, Pouli A, Kartasis Z, Delimpasi S, Gika D, Zomas A, Roussou M, Konstantopoulos K, Parcharidou A, Zervas K, Terpos E, Greek Myeloma Study Group.
    Ann Oncol; 2012 Mar; 23(3):722-729. PubMed ID: 21652580
    [Abstract] [Full Text] [Related]

  • 24. [Serum level of IL-17 in patients with multiple myeloma and its clinical significance].
    Zhang XL, Zhang WH, Fan XH, Wei F, Zhang M.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):930-2. PubMed ID: 22931657
    [Abstract] [Full Text] [Related]

  • 25. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.
    Hsiao LT, Yang CF, Yang SH, Gau JP, Yu YB, Hong YC, Liu CY, Liu JH, Chen PM, Chiou TJ, Tzeng CH.
    Eur J Haematol; 2012 Feb; 88(2):159-66. PubMed ID: 21973045
    [Abstract] [Full Text] [Related]

  • 26. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
    Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR.
    Semin Hematol; 2009 Apr; 46(2):110-7. PubMed ID: 19389494
    [Abstract] [Full Text] [Related]

  • 27. Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
    Schavgoulidze A, Lauwers-Cances V, Perrot A, Cazaubiel T, Chretien ML, Moreau P, Facon T, Leleu X, Karlin L, Stoppa AM, Decaux O, Belhadj K, Arnulf B, Mohty M, Ariette CM, Fohrer-Sonntag C, Lenain P, Marolleau JP, Tiab M, Araujo C, Orsini-Piocelle F, Jaccard A, Roussel M, Benboubker L, Eveillard JR, Dib M, Divoux M, Attal M, Avet-Loiseau H, Corre J.
    Haematologica; 2023 May 01; 108(5):1374-1384. PubMed ID: 36172814
    [Abstract] [Full Text] [Related]

  • 28. International Scoring System in Symptomatic Multiple Myeloma: Experience from a Tertiary Care Center.
    Sultan S, Irfan SM, Parveen S, Taufiq U.
    Asian Pac J Cancer Prev; 2016 May 01; 17(4):2031-3. PubMed ID: 27221891
    [Abstract] [Full Text] [Related]

  • 29. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.
    Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G, International Myeloma Working Group.
    Leukemia; 2013 Mar 01; 27(3):711-7. PubMed ID: 23032723
    [Abstract] [Full Text] [Related]

  • 30. Clinico-Pathological Profiles of Multiple Myeloma Patients in a Tertiary Care Hospital.
    Alam MM, Khan MA, Akter M, Wasim M, Rahman MH, Alam MN, Nahar R, Uddin MN, Kabir S, Pramanik MK, Ahmed MM, Chowdhury MAH, Basher MS, Islam GY.
    Mymensingh Med J; 2024 Jul 01; 33(3):840-847. PubMed ID: 38944730
    [Abstract] [Full Text] [Related]

  • 31. [Clinical Significance of Serum Free Light Chain and Its κ/λ Ratio in Patients with Multiple Myeloma].
    Zhao D, Jiang JQ, Lin L.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug 01; 27(4):1173-1178. PubMed ID: 31418375
    [Abstract] [Full Text] [Related]

  • 32. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
    Bila J, Jelicic J, Dencic Fekete M, Trajkovic G, Sretenovic A, Perunicic Jovanovic M, Antic D, Mihaljevic B.
    Oncol Res Treat; 2017 Aug 01; 40(10):616-620. PubMed ID: 28950269
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
    Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas D, Panagiotidis I, Kafantari E, Giannouli S, Zomas A, Konstantopoulos K, Dimopoulos MA.
    Haematologica; 2017 Mar 01; 102(3):593-599. PubMed ID: 27789676
    [Abstract] [Full Text] [Related]

  • 34. Diagnosis and treatment of multiple myeloma in Hunan Province.
    Liu F, Cheng Q, Song K, Yu H, Li J, Zhang H, Hu G, Zhou M, Wang J, Ding Z, Luo Z, Peng T, Ding L, Zhao L, Liu J, He Y, Peng H.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Apr 28; 47(4):497-504. PubMed ID: 35545345
    [Abstract] [Full Text] [Related]

  • 35. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.
    Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A.
    Biol Blood Marrow Transplant; 2018 Dec 28; 24(12):2443-2449. PubMed ID: 30142419
    [Abstract] [Full Text] [Related]

  • 36. [Correlation analysis of polyclonal plasma cell proportion in the bone marrow with clinical characteristics of patients with newly diagnosed multiple myeloma].
    Long XL, Wang XR, An N, Liu SY, Li Z, Li CH, Mu W, Wang D, Li CR.
    Zhonghua Xue Ye Xue Za Zhi; 2024 May 14; 45(5):475-480. PubMed ID: 38964922
    [Abstract] [Full Text] [Related]

  • 37. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
    D'Anastasi M, Notohamiprodjo M, Schmidt GP, Dürr HR, Reiser MF, Baur-Melnyk A.
    AJR Am J Roentgenol; 2014 Oct 14; 203(4):854-62. PubMed ID: 25247952
    [Abstract] [Full Text] [Related]

  • 38. Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma.
    Suehara Y, Takamatsu H, Fukumoto K, Fujisawa M, Narita K, Usui Y, Takeuchi M, Endean K, Matsue K.
    Cancer Sci; 2017 Feb 14; 108(2):187-192. PubMed ID: 27889936
    [Abstract] [Full Text] [Related]

  • 39. [Clinical Significance of Serum ADA Combined with GLB, CREA, β2-MG and HGB in Newly Diagnosed Multiple Myeloma].
    Qian H, Yuan HL, Zhang T, Yang YW, Feng JF.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun 14; 32(3):780-788. PubMed ID: 38926967
    [Abstract] [Full Text] [Related]

  • 40. Scintigraphy with technetium-99m methoxyisobutylisonitrile in multiple myeloma patients: correlation with the International Staging System.
    Koutsikos J, Grigoraki V, Athanasoulis T, Velidaki A, Mamoulakis C, Zomas A, Anagnostopoulos N, Georgiou E, Dimopoulos MA, Zerva C.
    Hell J Nucl Med; 2006 Jun 14; 9(3):177-80. PubMed ID: 17160159
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.